Paid Clinical Trials Maryland

Discover 2,155 paid clinical trials in Maryland. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 2,155

LurbinectedinStudy of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma

Recruiting

PHASE1

PHASE2

Sponsor:

Jazz Pharmaceuticals

Location:

Washington DC, Baltimore MD, Philadelphia PA, New York NYshow 11 more

Code:

NCT05734066

Conditions

Refractory Ewing Sarcoma

Relapsed Ewing Sarcoma

Ewing Sarcoma

Eligibility Criteria

Sex: All

Age: 2 - 30

Healthy Volunteers: Not accepted

Interventions

Lurbinectedin

Observational StudyA Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

Recruiting

Sponsor:

Target PharmaSolutions, Inc.

Location:

Washington DC, Rockville MD, Richmond VA, East Windsor NJshow 51 more

Code:

NCT03661866

Conditions

Atopic Dermatitis

Alopecia Areata

Hidradenitis Suppurativa

Vitiligo

Psoriasis

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Not accepted

DonanemabA Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Recruiting

PHASE3

Sponsor:

Eli Lilly and Company

Location:

Columbia MD, Arlington VA, Oxon Hill MD, Chantilly VAshow 172 more

Code:

NCT05026866

Conditions

Alzheimer Disease

Eligibility Criteria

Sex: All

Age: 65 - 70+

Healthy Volunteers: Not accepted

Interventions

Donanemab

Placebo

EtrasimodAn Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis

Recruiting

Sponsor:

Pfizer

Location:

Glen Burnie MD, Chevy Chase MD, New York NY, Chapel Hill NCshow 10 more

Code:

NCT06398626

Conditions

Colitis, Ulcerative

Eligibility Criteria

Sex: All

Age: 18 - 64

Healthy Volunteers: Not accepted

Interventions

Etrasimod

Buprenorphine & XR-NaltrexoneEfficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder

Recruiting

PHASE2

PHASE3

Sponsor:

New York State Psychiatric Institute

Location:

Rockville MD, New York NY

Code:

NCT05011266

Conditions

Opioid-use Disorder

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

Buprenorphine/naloxone

Placebo

BHV-7000Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

Recruiting

PHASE2

PHASE3

Sponsor:

Biohaven Therapeutics Ltd.

Location:

Washington DC, Baltimore MD, McLean VA, New York NYshow 27 more

Code:

NCT06309966

Conditions

Focal Epilepsy

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

BHV-7000

Placebo

SeralutinibEfficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

Recruiting

PHASE3

Sponsor:

GB002, Inc.

Location:

Washington DC, Baltimore MD, Falls Church VA, Philadelphia PAshow 51 more

Code:

NCT05934526

Conditions

Pulmonary Arterial Hypertension

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Placebo

Seralutinib

Generic Dry Powder Inhaler

Peer Recovery SupportEXPANDED SCOPE for Parent Grant Entitled, "Peer Recovery Support Services for Individuals in Recovery Residences on MOUD"

Recruiting

Sponsor:

Potomac Health Foundations

Location:

Baltimore MD

Code:

NCT06696157

Conditions

Opioid Use Disorder

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

PRSS intervention for MOUD initiation

Arlocabtagene AutoleucelStudy of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

Recruiting

PHASE2

Sponsor:

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Location:

Baltimore MD, Philadelphia PA, Norfolk VA, New Brunswick NJshow 34 more

Code:

NCT06297226

Conditions

Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Arlocabtagene Autoleucel (BMS-986393)

CamizestrantAn Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

Recruiting

PHASE3

Sponsor:

AstraZeneca

Location:

Bethesda MD, Washington DC, Annapolis MD, Baltimore MDshow 143 more

Code:

NCT05952557

Conditions

Breast Cancer, Early Breast Cancer

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Camizestrant

Tamoxifen

Anastrozole

Letrozole

Exemestane

Popular cities in Maryland

Annapolis Baltimore Rockville